Cargando…
Screening of placenta accreta spectrum disorder using maternal serum biomarkers and clinical indicators: a case–control study
BACKGROUND: Placenta accreta spectrum (PAS) disorder is a major cause of postpartum hemorrhage-associated maternal and fetal death, and novel methods for PAS screening are urgently needed for clinical application. METHODS: The purpose of this study was to develop new methods for PAS screening using...
Autores principales: | Zhou, Jiayi, Yang, Si, Xu, Xingneng, Xu, Xiuting, Wang, Xuwei, Ye, Anqi, Chen, Yanhong, He, Fang, Yu, Bolan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10334543/ https://www.ncbi.nlm.nih.gov/pubmed/37434137 http://dx.doi.org/10.1186/s12884-023-05784-2 |
Ejemplares similares
-
Maternal circulating biomarkers associated with placenta accreta spectrum disorders
por: Guo, Zhirong, et al.
Publicado: (2003) -
Potential Serum Biomarkers in Prenatal Diagnosis of Placenta Accreta Spectrum
por: Zhang, Tianyue, et al.
Publicado: (2022) -
The prenatal diagnostic indicators of placenta accreta spectrum disorders
por: Wu, Xiafei, et al.
Publicado: (2023) -
Effect of placenta location detected by ultrasound on the severity of placenta accreta spectrum in patients with placenta previa and placenta accreta spectrum
por: Liu, Hong, et al.
Publicado: (2023) -
Damage-Control Surgery for Maternal Near-Miss Cases of Placenta Previa and Placenta Accreta Spectrum
por: Rouzi, Abdulrahim A, et al.
Publicado: (2021)